+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pulmonary Arterial Hypertension Market Research Report by Drug Class, by State - United States Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5134265
  • Report
  • September 2021
  • Region: United States
  • 74 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The United States Pulmonary Arterial Hypertension Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Pulmonary Arterial Hypertension Market.

Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Pulmonary Arterial Hypertension to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the Pulmonary Arterial Hypertension Market was studied across Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5, and Prostacyclin & Prostacyclin Analog.
  • Based on Distribution, the Pulmonary Arterial Hypertension Market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on State, the Pulmonary Arterial Hypertension Market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pulmonary Arterial Hypertension Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Pulmonary Arterial Hypertension Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Pulmonary Arterial Hypertension Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Pulmonary Arterial Hypertension Market?
4. What is the competitive strategic window for opportunities in the United States Pulmonary Arterial Hypertension Market?
5. What are the technology trends and regulatory frameworks in the United States Pulmonary Arterial Hypertension Market?
6. What is the market share of the leading vendors in the United States Pulmonary Arterial Hypertension Market?
7. What modes and strategic moves are considered suitable for entering the United States Pulmonary Arterial Hypertension Market?
Note: Product cover images may vary from those shown
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Distribution Outlook
3.5. State Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges

6. Pulmonary Arterial Hypertension Market, by Drug Class
6.1. Introduction
6.2. Calcium Channel Blocker
6.3. Endothelin Receptor Antagonists
6.4. Phosphodiesterase 5
6.5. Prostacyclin & Prostacyclin Analog

7. Pulmonary Arterial Hypertension Market, by Distribution
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Online Pharmacy
7.4. Retail Pharmacy

8. California Pulmonary Arterial Hypertension Market
8.1. Introduction

9. Florida Pulmonary Arterial Hypertension Market
9.1. Introduction

10. Illinois Pulmonary Arterial Hypertension Market
10.1. Introduction

11. New York Pulmonary Arterial Hypertension Market
11.1. Introduction

12. Ohio Pulmonary Arterial Hypertension Market
12.1. Introduction

13. Pennsylvania Pulmonary Arterial Hypertension Market
13.1. Introduction

14. Texas Pulmonary Arterial Hypertension Market
14.1. Introduction

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion

16. Company Usability Profiles

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing

List of Figures
FIGURE 1. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
FIGURE 3. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2020 (USD MILLION)
FIGURE 4. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 5. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 6. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: MARKET DYNAMICS
FIGURE 7. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
FIGURE 8. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
FIGURE 9. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2026
FIGURE 10. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, 2018-2026 (USD MILLION)
FIGURE 11. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 12. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2026 (USD MILLION)
FIGURE 13. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 14. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, 2018-2026 (USD MILLION)
FIGURE 15. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 16. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, 2018-2026 (USD MILLION)
FIGURE 17. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 18. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (%)
FIGURE 19. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (USD MILLION)
FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2026
FIGURE 21. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2026 (USD MILLION)
FIGURE 22. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 23. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, 2018-2026 (USD MILLION)
FIGURE 24. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 25. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, 2018-2026 (USD MILLION)
FIGURE 26. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 27. CALIFORNIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 28. FLORIDA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 29. ILLINOIS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 30. NEW YORK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 31. OHIO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 32. PENNSYLVANIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 33. TEXAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 34. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: FPNV POSITIONING MATRIX
FIGURE 35. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 36. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE

List of Tables
TABLE 1. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 5. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY STATE, 2018-2026 (USD MILLION)
TABLE 6. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY STATE, 2018-2026 (USD MILLION)
TABLE 7. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, BY STATE, 2018-2026 (USD MILLION)
TABLE 8. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, BY STATE, 2018-2026 (USD MILLION)
TABLE 9. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD MILLION)
TABLE 10. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY STATE, 2018-2026 (USD MILLION)
TABLE 11. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY STATE, 2018-2026 (USD MILLION)
TABLE 12. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY STATE, 2018-2026 (USD MILLION)
TABLE 13. CALIFORNIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 14. FLORIDA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 15. ILLINOIS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 16. NEW YORK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 17. OHIO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 18. PENNSYLVANIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 19. TEXAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 20. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: SCORES
TABLE 21. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: BUSINESS STRATEGY
TABLE 22. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: PRODUCT SATISFACTION
TABLE 23. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: RANKING
TABLE 24. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 25. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: MERGER & ACQUISITION
TABLE 26. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 27. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 28. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: INVESTMENT & FUNDING
TABLE 29. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 30. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll